These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11652669)

  • 1. Who should rightfully decide whether a medical treatment necessarily incurred should be excluded from coverage under a health insurance policy provision which excludes from coverage "experimental" medical treatments?
    Fisfis BA
    Duquesne Law Rev; 1993; 31(4):777-800. PubMed ID: 11652669
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical insurance payments and patients involved in research.
    Holder AR
    IRB; 1994; 16(1-2):19-22. PubMed ID: 11652323
    [No Abstract]   [Full Text] [Related]  

  • 3. Undefined experimental treatment exclusions in health insurance contracts: a proposal for judicial response.
    Belk J
    Wash Law Rev; 1991 Jul; 66(3):809-30. PubMed ID: 11652624
    [No Abstract]   [Full Text] [Related]  

  • 4. Emerging technologies and medical coverage.
    Merrikin K; Smith S
    Clin Ethics Rep; 1996; 10(1):9-12. PubMed ID: 11660222
    [No Abstract]   [Full Text] [Related]  

  • 5. Funding innovative medical treatment.
    Holder AR
    Albany Law Rev; 1994; 57(3):795-810. PubMed ID: 11652865
    [No Abstract]   [Full Text] [Related]  

  • 6. Experimental drugs: more of them, but they're no longer free.
    Caplan J
    Hastings Cent Rep; 1987 Jun; 17(3):3. PubMed ID: 11644019
    [No Abstract]   [Full Text] [Related]  

  • 7. National Conference on Birth, Death, and Law: report.
    Andrews LB; Mariner WK;
    Jurimetrics; 1989; 29(4):403-36. PubMed ID: 11652560
    [No Abstract]   [Full Text] [Related]  

  • 8. Medical necessity, AIDS, and the law.
    Schultz GP; Pormenter CA
    St Louis Univ Public Law Rev; 1990; 9(2):379-420. PubMed ID: 11651112
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA's new rule on treatment use and sale of investigational new drugs.
    Levine RJ
    IRB; 1987; 9(4):1-4. PubMed ID: 11649946
    [No Abstract]   [Full Text] [Related]  

  • 10. Legal and regulatory perspectives in mass immunization programs.
    Ladimer I
    Insur Law J; 1976 Aug; (643):. PubMed ID: 11664613
    [No Abstract]   [Full Text] [Related]  

  • 11. In business to treat cancer.
    Henig RM
    N Y Times Mag; 1986 Nov; ():68, 70, 78, 80+. PubMed ID: 11647805
    [No Abstract]   [Full Text] [Related]  

  • 12. Who should rightfully decide whether a medical treatment necessarily incurred should be excluded from coverage under a health insurance policy provision which excludes from coverage "experimental" medical treatments?
    Fisfis BA
    Spec Law Dig Health Care Law; 1994 Mar; (181):9-32. PubMed ID: 10133063
    [No Abstract]   [Full Text] [Related]  

  • 13. Considering experimentation and elusive truth: informed consent made difficult.
    Brodeur D
    Issues (St Louis Mo); 1992; 7(2):1-8. PubMed ID: 11659444
    [No Abstract]   [Full Text] [Related]  

  • 14. Institutional review boards in the university setting: review of pharmaceutical testing protocols, informed consent and ethical concerns.
    Kobasic DM
    J Coll Univ Law; 1988; 15(2):185-216. PubMed ID: 11659168
    [No Abstract]   [Full Text] [Related]  

  • 15. AIDS and the American health care financing system.
    Greely HT
    Univ Pittsbg Law Rev; 1989; 51(1):73-166. PubMed ID: 11652563
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaccines and the law.
    Sanzo M
    Pepperdine Law Rev; 1991 Dec; 19(1):29-48. PubMed ID: 11659523
    [No Abstract]   [Full Text] [Related]  

  • 17. Setting limits in the dying zone: assisted suicide, scarce resources, and hard cases.
    Furrow BR
    Univ Detroit Mercy Law Rev; 1995; 72(4):901-26. PubMed ID: 11654374
    [No Abstract]   [Full Text] [Related]  

  • 18. Reimbursing new technologies: why are the courts judging experimental medicine?
    Saver RS
    Stanford Law Rev; 1992 May; 44(5):1095-131. PubMed ID: 10119850
    [No Abstract]   [Full Text] [Related]  

  • 19. Destructuring disability: rationing of health care and unfair discrimination against the sick.
    Orentlicher D
    Harv Civ Rights-Civil Lib Law Rev; 1996; 31(1):49-87. PubMed ID: 11660333
    [No Abstract]   [Full Text] [Related]  

  • 20. Confronting a new obstacle to reproductive choice: encouraging the development of RU-486 through reform of products liability law.
    Rubin LA
    Rev Law Soc Change; 1990-1991; 18(1):131-59. PubMed ID: 11656168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.